Literature DB >> 25711949

The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology.

Marcel J H Kenter1, Adam F Cohen.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25711949      PMCID： PMC4386939          DOI： 10.1111/bcp.12605

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

1.  Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.

Authors:  Paula S Römer; Susanne Berr; Elita Avota; Shin-Young Na; Manuela Battaglia; Ineke ten Berge; Hermann Einsele; Thomas Hünig
Journal:  Blood       Date:  2011-09-19       Impact factor: 22.113

2.  The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.

Authors:  Thomas Hünig
Journal:  Nat Rev Immunol       Date:  2012-04-10       Impact factor: 53.106

3.  Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.

Authors:  D Eastwood; L Findlay; S Poole; C Bird; M Wadhwa; M Moore; C Burns; R Thorpe; R Stebbings
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 4.  Establishing risk of human experimentation with drugs: lessons from TGN1412.

Authors:  M J H Kenter; A F Cohen
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

5.  Should we tolerate tolerability as an objective in early drug development?

Authors:  A Cohen
Journal:  Br J Clin Pharmacol       Date:  2007-09       Impact factor: 4.335

6.  Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial.

Authors:  Christopher Horvath; Laura Andrews; Andreas Baumann; Lauren Black; Diann Blanset; Joy Cavagnaro; Kenneth L Hastings; David L Hutto; Timothy K MacLachlan; Mark Milton; Theresa Reynolds; Stan Roberts; Mark Rogge; Jennifer Sims; George Treacy; Garvin Warner; James D Green
Journal:  Nat Rev Immunol       Date:  2012-08-31       Impact factor: 53.106

Review 7.  The use of biomarkers in human pharmacology (Phase I) studies.

Authors:  A F Cohen; J Burggraaf; J M A van Gerven; M Moerland; G J Groeneveld
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-06       Impact factor: 13.820

8.  Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist.

Authors:  Chia-Huey Lin; Thomas Hünig
Journal:  Eur J Immunol       Date:  2003-03       Impact factor: 5.532

Review 9.  On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development.

Authors:  P J Lowe; Y Hijazi; O Luttringer; H Yin; R Sarangapani; D Howard
Journal:  Xenobiotica       Date:  2007 Oct-Nov       Impact factor: 1.908

10.  Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists.

Authors:  Fred Lühder; Yun Huang; Kevin M Dennehy; Christine Guntermann; Ingrid Müller; Erna Winkler; Thomas Kerkau; Shinji Ikemizu; Simon J Davis; Thomas Hanke; Thomas Hünig
Journal:  J Exp Med       Date:  2003-04-21       Impact factor: 14.307
View more
  7 in total

Review 1.  Design and conduct of early phase drug studies in children: challenges and opportunities.

Authors:  Michael Rieder; Daniel Hawcutt
Journal:  Br J Clin Pharmacol       Date:  2016-08-08       Impact factor: 4.335

2.  Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.

Authors:  Joop van Gerven; Milton Bonelli
Journal:  Br J Clin Pharmacol       Date:  2018-05-30       Impact factor: 4.335

Review 3.  Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects.

Authors:  Joop van Gerven; Adam Cohen
Journal:  Br J Clin Pharmacol       Date:  2018-05-15       Impact factor: 4.335

Review 4.  [Immunotherapy in head and neck cancer].

Authors:  B Kansy; T Hussain; S Mattheis; B Wollenberg; S Brandau; S Lang
Journal:  HNO       Date:  2015-11       Impact factor: 1.284

Review 5.  Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.

Authors:  Marina A Dobrovolskaia
Journal:  J Control Release       Date:  2015-09-05       Impact factor: 9.776

6.  Improving public health by improving clinical trial guidelines and their application.

Authors:  Martin J Landray; Jeroen J Bax; Laurence Alliot; Marc Buyse; Adam Cohen; Rory Collins; Gerhard Hindricks; Stefan K James; Sile Lane; Aldo P Maggioni; Ann Meeker-O'Connell; Gunnar Olsson; Stuart J Pocock; Michael Rawlins; Jonathan Sellors; Kaori Shinagawa; Karin R Sipido; Liam Smeeth; Richard Stephens; Murray W Stewart; Wendy Gattis Stough; Fergus Sweeney; Frans Van de Werf; Kerrie Woods; Barbara Casadei
Journal:  Eur Heart J       Date:  2017-06-01       Impact factor: 29.983

Review 7.  Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.

Authors:  Ninh M La-Beck; Md Rakibul Islam; Maciej M Markiewski
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.